Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial

{ 'indexed': {'date-parts': [[2024, 3, 21]], 'date-time': '2024-03-21T07:20:24Z', 'timestamp': 1711005624185}, 'reference-count': 51, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2021, 7, 1]], 'date-time': '2021-07-01T00:00:00Z', 'timestamp': 1625097600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2021, 6, 5]], 'date-time': '2021-06-05T00:00:00Z', 'timestamp': 1622851200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc-nd/4.0/'}], 'funder': [ { 'DOI': '10.13039/501100003593', 'name': 'Conselho Nacional de Desenvolvimento Científico e Tecnológico', 'doi-asserted-by': 'publisher'}], 'content-domain': { 'domain': ['thelancet.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2021, 7]]}, 'DOI': '10.1016/j.eclinm.2021.100981', 'type': 'journal-article', 'created': {'date-parts': [[2021, 6, 27]], 'date-time': '2021-06-27T04:20:35Z', 'timestamp': 1624767635000}, 'page': '100981', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 51, 'title': 'Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept ' 'randomized double-blind clinical trial.', 'prefix': '10.1016', 'volume': '37', 'author': [ {'given': 'Vinicius Fontanesi', 'family': 'Blum', 'sequence': 'first', 'affiliation': []}, {'given': 'Sérgio', 'family': 'Cimerman', 'sequence': 'additional', 'affiliation': []}, {'given': 'James R', 'family': 'Hunter', 'sequence': 'additional', 'affiliation': []}, {'given': 'Paulo', 'family': 'Tierno', 'sequence': 'additional', 'affiliation': []}, {'given': 'Acioly', 'family': 'Lacerda', 'sequence': 'additional', 'affiliation': []}, {'given': 'Alexandre', 'family': 'Soeiro', 'sequence': 'additional', 'affiliation': []}, {'given': 'Florentino', 'family': 'Cardoso', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nancy Cristina', 'family': 'Bellei', 'sequence': 'additional', 'affiliation': []}, {'given': 'Juliana', 'family': 'Maricato', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nathalia', 'family': 'Mantovani', 'sequence': 'additional', 'affiliation': []}, {'given': 'Marcella', 'family': 'Vassao', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-8517-600X', 'authenticated-orcid': False, 'given': 'Danilo', 'family': 'Dias', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-3413-005X', 'authenticated-orcid': False, 'given': 'Juliana', 'family': 'Galinskas', 'sequence': 'additional', 'affiliation': []}, {'given': 'Luis Mário Ramos', 'family': 'Janini', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Joanna Reis', 'family': 'Santos-Oliveira', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-7455-2447', 'authenticated-orcid': False, 'given': 'Alda Maria', 'family': 'Da-Cruz', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ricardo Sobhie', 'family': 'Diaz', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.eclinm.2021.100981_bib0001', 'doi-asserted-by': 'crossref', 'unstructured': 'Valencia D.N. Brief Review on COVID-19: the 2020 pandemic caused by ' 'SARS-CoV-2. Cureus. 2020; 12. doi:10.7759/cureus.7386.', 'DOI': '10.7759/cureus.7386'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0002', 'doi-asserted-by': 'crossref', 'DOI': '10.1183/13993003.01028-2020', 'article-title': 'Clinical phenotypes of SARS-CoV-2: implications for clinicians and ' 'researchers', 'volume': '55', 'author': 'Rello', 'year': '2020', 'journal-title': 'Eur Respir J'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0003', 'doi-asserted-by': 'crossref', 'first-page': '1708', 'DOI': '10.1056/NEJMoa2002032', 'article-title': 'Clinical Characteristics of Coronavirus Disease 2019 in China', 'volume': '382', 'author': 'Guan', 'year': '2020', 'journal-title': 'N Engl J Med'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0004', 'doi-asserted-by': 'crossref', 'first-page': '1730', 'DOI': '10.1111/all.14238', 'article-title': 'Clinical characteristics of 140 patients infected with SARS-CoV-2 in ' 'Wuhan, China', 'volume': '75', 'author': 'Zhang', 'year': '2020', 'journal-title': 'Allergy'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0005', 'doi-asserted-by': 'crossref', 'first-page': '1455', 'DOI': '10.1152/physrev.00020.2020', 'article-title': 'SARS-CoV-2 and COVID-19: from the bench to the bedside', 'volume': '100', 'author': 'Romagnoli', 'year': '2020', 'journal-title': 'Physiological Reviews'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0006', 'doi-asserted-by': 'crossref', 'first-page': '1054', 'DOI': '10.1016/S0140-6736(20)30566-3', 'article-title': 'Clinical course and risk factors for mortality of adult inpatients with ' 'COVID-19 in Wuhan, China: a retrospective cohort study', 'volume': '395', 'author': 'Zhou', 'year': '2020', 'journal-title': 'The Lancet'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0007', 'doi-asserted-by': 'crossref', 'first-page': '1708', 'DOI': '10.3389/fimmu.2020.01708', 'article-title': 'Cytokine Storm in COVID-19: the current evidence and treatment ' 'strategies', 'volume': '11', 'author': 'Tang', 'year': '2020', 'journal-title': 'Front Immunol'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0008', 'doi-asserted-by': 'crossref', 'first-page': '607', 'DOI': '10.1016/j.jinf.2020.03.037', 'article-title': 'The pathogenesis and treatment of the ‘Cytokine Storm” in COVID-19', 'volume': '80', 'author': 'Ye', 'year': '2020', 'journal-title': 'Journal of Infect'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0009', 'doi-asserted-by': 'crossref', 'first-page': '497', 'DOI': '10.1016/S0140-6736(20)30183-5', 'article-title': 'Clinical features of patients infected with 2019 novel coronavirus in ' 'Wuhan, China', 'volume': '395', 'author': 'Huang', 'year': '2020', 'journal-title': 'The Lancet'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0010', 'first-page': '1', 'article-title': 'Viral load dynamics and disease severity in patients infected with ' 'SARS-CoV-2 in Zhejiang province, China, January-March 2020: ' 'retrospective cohort study', 'volume': '369', 'author': 'Zheng', 'year': '2020', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0011', 'doi-asserted-by': 'crossref', 'first-page': '1435', 'DOI': '10.1164/rccm.202003-0572LE', 'article-title': 'SARS-CoV-2 viral load in clinical samples from critically ill patients', 'volume': '201', 'author': 'Huang', 'year': '2020', 'journal-title': 'Am J Respir Crit Care Med'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0012', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1371/journal.ppat.1008737', 'article-title': 'Interplay between SARS-CoV-2 and the type I interferon response', 'volume': '16', 'author': 'Ribero', 'year': '2020', 'journal-title': 'PLoS Pathog'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0013', 'doi-asserted-by': 'crossref', 'first-page': '211', 'DOI': '10.14740/jmc3520', 'article-title': 'Macrophage activation in COVID-19 patients in intensive care unit', 'volume': '11', 'author': 'Labro', 'year': '2020', 'journal-title': 'J Med Cases'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0014', 'doi-asserted-by': 'crossref', 'DOI': '10.1038/s41577-020-0317-2', 'article-title': 'Macrophages: a Trojan horse in COVID-19?', 'volume': '20', 'author': 'Park', 'year': '2020', 'journal-title': 'Nat Rev Immunol'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0015', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.lfs.2020.118102', 'article-title': 'Contribution of monocytes and macrophages to the local tissue ' 'inflammation and cytokine storm in COVID-19: lessons from SARS and ' 'MERS, and potential therapeutic interventions', 'volume': '257', 'author': 'Jafarzadeh', 'year': '2020', 'journal-title': 'Life Sci'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0016', 'doi-asserted-by': 'crossref', 'first-page': '473', 'DOI': '10.1126/science.abb8925', 'article-title': 'Cytokine release syndrome in severe COVID-19', 'volume': '368', 'author': 'Moore', 'year': '2020', 'journal-title': 'Science'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0017', 'doi-asserted-by': 'crossref', 'first-page': '13', 'DOI': '10.1016/j.cytogfr.2020.05.009', 'article-title': 'IL-6: relevance for immunopathology of SARS-CoV-2', 'volume': '53', 'author': 'Gubernatorova', 'year': '2020', 'journal-title': 'Cytokine Growth Fact Rev'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0018', 'first-page': '1', 'article-title': 'Virology, transmission, and pathogenesis of SARS-CoV-2', 'volume': '371', 'author': 'Cevik', 'year': '2020', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0019', 'doi-asserted-by': 'crossref', 'first-page': '417', 'DOI': '10.1002/jmv.20556', 'article-title': 'Cytokine regulation in SARS coronavirus infection compared to other ' 'respiratory virus infections', 'volume': '78', 'author': 'Okabayashi', 'year': '2006', 'journal-title': 'J Med Virol'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0020', 'doi-asserted-by': 'crossref', 'first-page': '4', 'DOI': '10.3389/fimmu.2020.01441', 'article-title': 'Immune Response, Inflammation, and the Clinical Spectrum of COVID-19', 'volume': '11', 'author': 'García', 'year': '2020', 'journal-title': 'Front Immunol'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0021', 'doi-asserted-by': 'crossref', 'first-page': '762', 'DOI': '10.1093/cid/ciaa248', 'article-title': 'Dysregulation of immune response in patients with coronavirus 2019 ' '(COVID-19) in Wuhan, China', 'volume': '71', 'author': 'Qin', 'year': '2020', 'journal-title': 'Clinical Infectious Diseases'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0022', 'doi-asserted-by': 'crossref', 'first-page': '420', 'DOI': '10.1016/S2213-2600(20)30076-X', 'article-title': 'Pathological findings of COVID-19 associated with acute respiratory ' 'distress syndrome', 'volume': '8', 'author': 'Xu', 'year': '2020', 'journal-title': 'Lancet Respir Med'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0023', 'doi-asserted-by': 'crossref', 'first-page': '94', 'DOI': '10.1016/j.antiviral.2014.07.014', 'article-title': 'Nitazoxanide: a first-in-class broad-spectrum antiviral agent', 'volume': '110', 'author': 'Rossignol', 'year': '2014', 'journal-title': 'Antiviral Res'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0024', 'doi-asserted-by': 'crossref', 'first-page': '227', 'DOI': '10.1016/j.jiph.2016.04.001', 'article-title': 'Nitazoxanide, a new drug candidate for the treatment of Middle East ' 'respiratory syndrome coronavirus', 'volume': '9', 'author': 'Rossignol', 'year': '2016', 'journal-title': 'J Infect Public Health'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0025', 'doi-asserted-by': 'crossref', 'first-page': '398', 'DOI': '10.1016/j.virol.2018.03.023', 'article-title': 'Inhibition of vaccinia virus replication by Nitazoxanide', 'volume': '518', 'author': 'Hickson', 'year': '2018', 'journal-title': 'Virology'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0026', 'doi-asserted-by': 'crossref', 'first-page': '29798', 'DOI': '10.1074/jbc.M109.029470', 'article-title': 'Thiazolides, a new class of anti-influenza molecules targeting viral ' 'hemagglutinin at the post-translational level', 'volume': '284', 'author': 'Rossignol', 'year': '2009', 'journal-title': 'J Biol Chem'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0027', 'doi-asserted-by': 'crossref', 'first-page': '531', 'DOI': '10.3389/fimmu.2019.00531', 'article-title': 'Drug repurposing approaches for the treatment of influenza viral ' 'infection: reviving old drugs to fight against a long-lived enemy', 'volume': '10', 'author': 'Pizzorno', 'year': '2019', 'journal-title': 'Front Immunol'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0028', 'doi-asserted-by': 'crossref', 'first-page': '609', 'DOI': '10.1016/S1473-3099(14)70717-0', 'article-title': 'Effect of Nitazoxanide in adults and adolescents with acute ' 'uncomplicated influenza: a double-blind, randomised, ' 'placebo-controlled, phase 2b/3 trial', 'volume': '14', 'author': 'Haffizulla', 'year': '2014', 'journal-title': 'Lancet Infect Dis'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0029', 'doi-asserted-by': 'crossref', 'first-page': '873', 'DOI': '10.1016/j.ymthe.2020.12.016', 'article-title': 'Synergistic and antagonistic drug combinations against SARS-CoV-2', 'volume': '29', 'author': 'Bobrowski', 'year': '2021', 'journal-title': 'Molecular Therapy'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0030', 'doi-asserted-by': 'crossref', 'first-page': '775', 'DOI': '10.1002/cpt.1909', 'article-title': 'Prioritization of Anti-SARS-Cov-2 drug repurposing opportunities based ' 'on plasma and target site concentrations derived from their established ' 'human Pharmacokinetics', 'volume': '108', 'author': 'Arshad', 'year': '2020', 'journal-title': 'Clin Pharmacol Ther'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0031', 'doi-asserted-by': 'crossref', 'first-page': '221', 'DOI': '10.5414/CPP40221', 'article-title': 'Nitazoxanide pharmacokinetics and tolerability in man during 7 days ' 'dosing with 0.5g and 1g b.i.d', 'volume': '40', 'author': 'Stockis', 'year': '2002', 'journal-title': 'CP'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0032', 'doi-asserted-by': 'crossref', 'first-page': '52', 'DOI': '10.1016/S2055-6640(20)30017-0', 'article-title': 'Review of safety and minimum pricing of nitazoxanide for potential ' 'treatment of COVID-19', 'volume': '6', 'author': 'Pepperrell', 'year': '2020', 'journal-title': 'Journal of Virus Eradication'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0033', 'unstructured': 'World Health Organization. 2020 COVID-19 therapeutic trial synopsis. ' 'https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0034', 'unstructured': 'Helios M., Rosario D. Package PWR title basic functions for power ' 'analysis. 2020.'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0035', 'unstructured': 'R: a language and environment for statistical computing. 2020 Available ' 'from: ' 'https://www.gbif.org/pt/tool/81287/r-a-language-and-environment-for-statistical-computing'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0036', 'first-page': '59', 'article-title': 'Thalidomide is associated with increased T cell activation and ' 'inflammation in Antiretroviral-naive HIV-infected individuals in a ' 'randomised clinical trial of efficacy and safety', 'volume': '23', 'author': 'Vergara', 'year': '2017', 'journal-title': 'E Bio Med'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0037', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ejphar.2020.173748', 'article-title': 'A review on possible mechanistic insights of Nitazoxanide for ' 'repurposing in COVID-19', 'volume': '891', 'author': 'Lokhande', 'year': '2021', 'journal-title': 'Eur J Pharmacol'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0038', 'article-title': 'Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or ' 'chemoprophylaxis', 'volume': '15', 'author': 'Rajoli', 'year': '2020', 'journal-title': 'Br J Clin Pharmacol'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0039', 'doi-asserted-by': 'crossref', 'DOI': '10.1001/jamanetworkopen.2020.8857', 'article-title': 'Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive ' 'therapy for patients hospitalized with severe acute respiratory ' 'syndrome coronavirus 2 SARS-CoV-2 infection: a randomized clinical ' 'trial', 'volume': '3', 'author': 'Borba', 'year': '2020', 'journal-title': 'JAMA Netw Open'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0040', 'article-title': 'Plasma CRP level is positively associated with the severity of COVID-19', 'volume': '15', 'author': 'Chen', 'year': '2020', 'journal-title': 'Ann Clin Microbiol Antimicrob'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0041', 'doi-asserted-by': 'crossref', 'first-page': '846', 'DOI': '10.1007/s00134-020-05991-x', 'article-title': 'Clinical predictors of mortality due to COVID-19 based on an analysis ' 'of data of 150 patients from Wuhan, China', 'volume': '46', 'author': 'Ruan', 'year': '2020', 'journal-title': 'Intens Care Med'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0042', 'doi-asserted-by': 'crossref', 'first-page': '1123', 'DOI': '10.1080/22221751.2020.1770129', 'article-title': 'Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 ' 'are disease severity predictors', 'volume': '9', 'author': 'Han', 'year': '2020', 'journal-title': 'Emerg Microbes Infect'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0043', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.lfs.2020.118167', 'article-title': 'The role of cytokine profile and lymphocyte subsets in the severity of ' 'coronavirus disease 2019 (COVID-19): a systematic review and ' 'meta-analysis', 'volume': '258', 'author': 'Akbari', 'year': '2020', 'journal-title': 'Life Sci'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0044', 'doi-asserted-by': 'crossref', 'first-page': '1636', 'DOI': '10.1038/s41591-020-1051-9', 'article-title': 'An inflammatory cytokine signature predicts COVID-19 severity and ' 'survival', 'volume': '26', 'author': 'Del Valle', 'year': '2020', 'journal-title': 'Nat Med'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0045', 'doi-asserted-by': 'crossref', 'first-page': '1407', 'DOI': '10.1016/S0140-6736(20)30858-8', 'article-title': 'Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently ' 'needed', 'volume': '395', 'author': 'Feldmann', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0046', 'doi-asserted-by': 'crossref', 'first-page': '1045', 'DOI': '10.1172/JCI114265', 'article-title': 'Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that ' 'activates neutrophils', 'volume': '84', 'author': 'Baggiolini', 'year': '1989', 'journal-title': 'J Clin Invest'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0047', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pone.0241659', 'article-title': 'Lymphopenia predicted illness severity and recovery in patients with ' 'COVID-19: a single-center, retrospective study', 'volume': '15', 'author': 'Liu', 'year': '2020', 'journal-title': 'PLoS ONE'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0048', 'doi-asserted-by': 'crossref', 'first-page': '13', 'DOI': '10.1002/JLB.4HI0720-470R', 'article-title': 'Frontline Science: COVID-19 infection induces readily detectable ' 'morphologic and inflammation-related phenotypic changes in peripheral ' 'blood monocytes', 'volume': '109', 'author': 'Zhang', 'year': '2021', 'journal-title': 'J Leukoc Biol'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0049', 'doi-asserted-by': 'crossref', 'first-page': '710', 'DOI': '10.1016/j.molcel.2020.07.027', 'article-title': 'Coronavirus RNA proofreading: molecular basis and therapeutic targeting', 'volume': '79', 'author': 'Robson', 'year': '2020', 'journal-title': 'Molecular Cell'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0050', 'article-title': 'COVID-19 epidemic in the Brazilian state of Amazonas was driven by ' 'long-term persistence of endemic SARS-CoV-2 lineages and the recent ' 'emergence of the new Variant of Concern P.1', 'author': 'Naveca', 'year': '2021', 'journal-title': 'Review'}, { 'key': '10.1016/j.eclinm.2021.100981_bib0051', 'article-title': 'Early use of nitazoxanide in mild Covid-19 disease: randomised, ' 'placebo-controlled trial', 'author': 'Rocco', 'year': '2020', 'journal-title': 'Eur Respir J'}], 'container-title': 'eClinicalMedicine', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S2589537021002613?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S2589537021002613?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 12, 14]], 'date-time': '2022-12-14T08:17:27Z', 'timestamp': 1671005847000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S2589537021002613'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 7]]}, 'references-count': 51, 'alternative-id': ['S2589537021002613'], 'URL': 'http://dx.doi.org/10.1016/j.eclinm.2021.100981', 'relation': {}, 'ISSN': ['2589-5370'], 'subject': ['General Medicine'], 'container-title-short': 'eClinicalMedicine', 'published': {'date-parts': [[2021, 7]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove ' 'of concept randomized double-blind clinical trial.', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'eClinicalMedicine', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.eclinm.2021.100981', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2021 The Authors. Published by Elsevier Ltd.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '100981'}